SCHEMBL6285846

SCHEMBL6285846

CN(C)c1cccc2cccc(N(C)C)c12.CN(C)c1cccc2cccc(N(C)C)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 1.00
KDM4E B2RXH2 6/20 1.00
GAA P10253 5/20 1.00
MCL1 Q07820 1/20 0.47
ALDH1A1 P00352 9/20 0.45
TSHR P16473 5/20 0.45
HSD17B10 Q99714 5/20 0.45
HPGD P15428 4/20 0.45
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 2/20 0.45
CYP1A1 P04798 1/20 0.45
CYP1B1 Q16678 1/20 0.45
SIGMAR1 Q99720 1/20 0.40
TP53 P04637 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 4/20 0.39
NSD2 O96028 2/20 0.39
LMNA P02545 2/20 0.39
MAPK1 P28482 2/20 0.39
TDP1 Q9NUW8 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29363940 1.00 MAPT (1.00) MAPTKDM4EGAAMCL1ALDH1A1
SCHEMBL28279 1.00 MAPT (1.00) MAPTKDM4EGAAMCL1ALDH1A1
Ammonia Solution, Strong SCHEMBL6838810 0.97 MAPT (0.95) MAPTKDM4EGAAMCL1ALDH1A1
Ammonia Solution, Strong SCHEMBL9336609 0.97 MAPT (0.95) MAPTKDM4EGAAMCL1ALDH1A1
Hydrochloric Acid SCHEMBL9815129 0.97 MAPT (0.95) MAPTKDM4EGAAMCL1ALDH1A1
SCHEMBL30833304 0.97 MAPT (0.95) MAPTKDM4EGAAMCL1ALDH1A1
SCHEMBL1509347 0.92 MAPT (0.85) MAPTKDM4EGAAMCL1ALDH1A1
N,N-Dimethylethanaminium SCHEMBL8487667 0.89 KDM4E (0.78) MAPTKDM4EGAAMCL1ALDH1A1
Formic Acid SCHEMBL7595259 0.87 MAPT (0.75) MAPTKDM4EGAAMCL1ALDH1A1
Phosphoric Acid SCHEMBL9139860 0.87 MAPT (0.75) MAPTKDM4EGAAMCL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278989-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM ASTEX THERAPEUTICS LIMITED (GB) 2023-09-07 US claimed
US-20210101887-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM ASTEX THERAPEUTICS LIMITED (GB) 2021-04-08 US claimed
US-20230278989-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM ASTEX THERAPEUTICS LIMITED (GB) 2023-09-07 US disclosed
US-11603367-B2 Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them ASTEX THERAPEUTICS LIMITED (GB) 2023-03-14 US disclosed
US-20210101887-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM ASTEX THERAPEUTICS LIMITED (GB) 2021-04-08 US disclosed
US-20050164125-A1 Forming layer of photoimageable composition on a substrate surface exposed to pattern of radiation which produces a catalyst capable of changing photoimageable composition's susceptibility to a developer SANDIA NATIONAL LABORATORIES (US) 2005-07-28 US disclosed
US-20050118529-A1 Photoimageable composition SANDIA NATIONAL LABORATORIES (US) 2005-06-02 US disclosed
US-6858378-B1 Forming a layer of photoimageable composition on a substrate surface; exposing to pattern of radiation which produces a catalyst capable of changing photoimageable composition's susceptibility to a developer; applying a developer to remove SANDIA NATIONAL LABORATORIES (US) 2005-02-22 US disclosed
US-6645696-B1 Selected buffering amines in a photoimageable composition prevents process bias which with conventional photoresists causes designed features to be distorted, especially in corners and high resolution features. Amines reacted with EUV LLC. 2003-11-11 US disclosed
US-4963552-A HYPOTENSIVE AGENTS, ANTIDEPRESSANTS AMERICAN CYANAMID COMPANY (US) 1990-10-16 US disclosed
US-4916137-A 5-(Substituted-amino)-8-(phenyl or substituted-phenyl)-3H,6H-1,4,5A,8A-tetraazaacenaphthylen-3-ones and treatment of neural behavior disorders AMERICAN CYANAMID COMPANY (US) 1990-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11603367-B2 Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them MDM2, TP53, TP53BP1 MAPT 1045/4885KDM4E 3104/4885GAA 3070/4885
US-20230278989-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM MDM2, TP53, TP53BP1 MAPT 1045/4885KDM4E 3104/4885GAA 3070/4885
US-20210101887-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM MDM2, TP53, TP53BP1 MAPT 1045/4885KDM4E 3104/4885GAA 3070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.